|
Clinical features of tumors, immunohistochemistry of tru-cut core biopsies before chemotherapy, and reverse-transcriptase-mediated polymerase chain reaction (RT-PCR) after chemotherapy |
||||||||||||
| Number of |
c494 |
MDR1 |
||||||||||
| Histology |
Size |
invaded nodes |
erb |
p53 |
Ki67 (%) |
ER |
PR |
MDR1 |
LRP |
Chemotherapy |
Response |
(RT-PCR) |
|
|
||||||||||||
| Lobular |
8.0 |
32 |
0 |
0 |
30 |
0 |
0 |
FAC4 |
SD |
0 |
||
| Ductal |
7.0 |
31 |
1 |
1 |
60 |
0 |
0 |
Ttere-ADM4 |
PR |
1 |
||
| Ductal |
6.0 |
21 |
1 |
1 |
30 |
1 |
1 |
1 |
FAC4 |
PR |
1 |
|
| Ductal |
3.5 (T4b) |
20 |
1 |
0 |
5 |
0 |
0 |
0 |
1 |
FAC3 |
PR |
1 |
| Ductal |
6.0 |
20 |
0 |
0 |
35 |
0 |
0 |
1 |
1 |
FAC4 |
SD |
1 |
| Lobular |
7.0 |
18 |
0 |
0 |
20 |
1 |
1 |
FAC4 |
PR |
0 |
||
| Ductal |
3 (T4b) |
16 |
0 |
0 |
30 |
1 |
1 |
0 |
1 |
FAC4 |
PR |
1 |
| Ductal |
Diffuse |
15 |
0 |
0 |
20 |
0 |
0 |
FAC4 |
PR |
0 |
||
| Lobular |
Diffuse |
11 |
0 |
0 |
80 |
1 |
1 |
1 |
1 |
FAC6 |
PR |
1 |
| Ductal |
2.2 (T4b) |
10 |
0 |
1 |
30 |
0 |
0 |
0 |
1 |
FAC4 |
PR |
0 |
| Ductal |
7.0 |
10 |
0 |
0 |
35 |
1 |
0 |
1 |
1 |
FAC4 |
PR |
1 |
| Ductal |
3 (T4b) |
10 |
1 |
1 |
20 |
1 |
1 |
FAC4 |
PR |
Failed |
||
| Ductal |
5.0 |
9 |
1 |
0 |
20 |
0 |
0 |
FAC4 |
SD |
Failed |
||
| Ductal |
2.2+1.3 |
9 |
1 |
0 |
50 |
1 |
1 |
0 |
1 |
FAC4 |
PR |
1 |
| Ductal |
4.0 (T4b) |
8 |
1 |
1 |
1 |
1 |
FAC4 |
PR |
0 |
|||
| Lobular |
3.0 |
8 |
0 |
0 |
2 |
1 |
1 |
0 |
FAC4 |
SD |
0 |
|
| Ductal |
Diffuse |
7 |
1 |
0 |
20 |
1 |
0 |
1 |
FAC4 |
SD |
1 |
|
| Ductal |
8.0 |
7 |
1 |
1 |
50 |
0 |
0 |
1 |
1 |
FAC4 |
CCR |
1 |
| Ductal |
5.0 (T4b) |
5 |
0 |
0 |
5 |
0 |
0 |
FAC3 |
PR |
0 |
||
| Ductal |
Diffuse |
4 |
0 |
0 |
50 |
1 |
0 |
1 |
FAC4 |
PR |
1 |
|
| Ductal |
10.0 |
3 |
0 |
0 |
80 |
0 |
0 |
1 |
FAC3 |
PR |
Failed |
|
| Ductal |
6.0 |
3 |
1 |
0 |
40 |
0 |
0 |
1 |
FAC4 |
SD |
0 |
|
| Ductal |
4.5 (T4b) |
2 |
0 |
0 |
30 |
1 |
1 |
FAC6 |
SD |
1 |
||
| Ductal |
2.5 |
2 |
0 |
0 |
no |
0 |
0 |
FAC4 |
PR |
Failed |
||
| Ductal |
10.0 |
2 |
0 |
1 |
60 |
0 |
0 |
FAC4 |
CCR |
1 |
||
| Ductal |
4.5+2.0 |
2 |
0 |
0 |
25 |
1 |
1 |
0 |
0 |
CMF4 |
PR |
0 |
| Ductal |
5.0 |
2 |
1 |
1 |
40 |
1 |
0 |
0 |
FAC4 |
PR |
0 |
|
| Ductal |
3.5 |
2 |
0 |
0 |
15 |
1 |
1 |
0 |
1 |
FAC4 |
SD |
0 |
| Ductal |
3.0 |
2 |
0 |
1 |
35 |
0 |
0 |
1 |
FAC4 |
SD |
0 |
|
| Ductal |
2.0 |
2 |
0 |
0 |
30 |
1 |
0 |
1 |
FAC4 |
PR |
1 |
|
| Ductal |
2.6+2.3 |
1 |
0 |
0 |
40 |
1 |
1 |
FAC3 |
PR |
1 |
||
| Ductal |
3.5 |
1 |
0 |
0 |
15 |
1 |
1 |
1 |
1 |
FAC4 |
PR |
1 |
| Undiff. |
6.0 |
1 |
0 |
1 |
45 |
0 |
0 |
FAC6 |
SD |
1 |
||
| Lobular |
6.0 |
1 |
0 |
0 |
10 |
1 |
1 |
0 |
0 |
FAC4 |
PR |
0 |
| Ductal |
3.0 |
1 |
0 |
1 |
70 |
0 |
0 |
1 |
1 |
FAC2 |
PR |
1 |
| Ductal |
5+2 |
0 |
1 |
1 |
20 |
0 |
1 |
FAC3 |
PR |
Failed |
||
| Ductal |
3.5 |
0 |
1 |
0 |
12 |
0 |
0 |
0 |
0 |
FAC3 |
PR |
0 |
| Ductal |
10.0 |
0 |
0 |
1 |
15 |
0 |
0 |
FAC5 |
SD |
0 |
||
| Ductal |
6.0 |
0 |
0 |
1 |
15 |
1 |
1 |
FAC4 |
PR |
1 |
||
| Lobular |
5.0 |
0 |
0 |
0 |
10 |
1 |
1 |
1 |
0 |
FAC4 |
PR |
0 |
| Ductal |
5.0 |
0 |
0 |
0 |
10 |
1 |
1 |
FAC4 |
PR |
0 |
||
| Ductal |
4.0 |
0 |
0 |
0 |
10 |
0 |
0 |
0 |
0 |
FAC4 |
PR |
0 |
| Ductal |
5.0 |
0 |
0 |
0 |
10 |
1 |
1 |
0 |
1 |
FAC4 |
PR |
ND |
| Ductal |
6.0 |
0 |
1 |
1 |
25 |
1 |
1 |
FAC4 |
PR |
1 |
||
| Ductal |
2.0 (T4a) |
0 |
1 |
1 |
30 |
1 |
1 |
FAC4 |
SD |
0 |
||
| Ductal |
5.0 |
0 |
0 |
0 |
25 |
1 |
0 |
0 |
0 |
FAC4 |
PR |
0 |
| Ductal |
5.0 |
0 |
0 |
0 |
15 |
1 |
1 |
0 |
0 |
FAC4 |
PR |
0 |
| Ductal |
6.0 |
0 |
0 |
1 |
80 |
0 |
0 |
0 |
1 |
FAC4 |
PR |
1 |
| Ductal |
3.6 |
0 |
0 |
0 |
10 |
1 |
1 |
1 |
1 |
FAC4 |
SD |
0 |
| Ductal |
3.5 |
0 |
0 |
1 |
15 |
0 |
0 |
1 |
FAC4 |
PR |
1 |
|
| Ductal |
4.0 |
0 |
0 |
0 |
20 |
1 |
0 |
1 |
FAC4 |
PR |
0 |
|
| Ductal |
5.0 |
0 |
0 |
0 |
10 |
1 |
1 |
1 |
FAC4 |
PR |
0 |
|
|
Responses: 1, positive, 0, negative. Positivity levels: MDR1 (c494), only membrane staining in more than 10% of tumor cells; LRP, more than 20% reactive cells (for details, see the text). CCR, complete clinical response; PR, partial response; SD, stable disease; F, 5-fluorouracyl; A, doxorubicin (adriamycin); C, cyclophosphamide; M, methotrexate; undiff, undifferentiated; ND, not done; Ttere, taxotere. | ||||||||||||
Schneider et al. Breast Cancer Res 2001 3:183 doi:10.1186/bcr293 |
||||||||||||